Maternal outcome of a cohort of women with SLE with and without lupus nephritis.
| Characteristics | No Previous Lupus Nephritis, n = 64 | Previous Lupus Nephritis, n = 43 |
|---|---|---|
| Preeclampsia, n (%) | 10 (16) | 12 (28) |
| Gestation of preeclampsia onset, weeks, median (range) | 37.5 (35–38) | 34.5 (32–37)† |
| Mode of delivery, n (%) | ||
| Caesarean birth | 22 (34) | 17 (40) |
| Emergency | 17 (27) | 14 (33) |
| Flare, n (%) | 25 (40) | 14 (36) |
| Renal flare | 1 new (1.5) | 6 (14) |
| Time to first flare, weeks | ||
| Median (range) | 22 (16–28) | 20 (16–24) |
| Postnatal flare | 2 | 0 |
| Treatment given during flare | ||
| Prednisolone started | 3 | 0 |
| Prednisolone increased | 17 | 12 |
| Azathioprine increased | 0 | 2 |
| Prednisolone declined | 4 | 0 |
| Hydroxychloroquine started | 1 | 0 |
| No immunosuppression during pregnancy, n (%) | 20 (31) | 3 (7)†† |
| Bilateral uterine artery notches to predict preeclampsia/SGA | 9/58 (16%) | 0/40 (0%) |
| Sensitivity | 60% | 0% |
| Specificity | 87% | 100% |
| PPV | 44% | — |
| NPV | 85% | 47% |
| Postpartum creatinine | n = 45 | n = 38 |
| Median (IQR) | 62 (56–71) | 67* (58–94) |
| Postpartum eGFR, ml/min/1.73m2, median (IQR) | 105 (94–123) | 95** (68–118) |
| Months followup, median (IQR) | 39 (23–63) | 39 (19–64) |